盤中異動 | 阿裏健康盤中上漲8%,報於5.4港元
2022年11月15日11時35分,阿裏健康(HK00241)盤中上漲8%,報於5.4港元,成交額達4.68億港元,換手率達到0.62%。
11月7日訊,1月7日消息,在第五屆中國國際進口博覽會上,輝瑞中國與阿裏健康簽署疾病教育創新合作戰略協議。在繼往合作基礎上,雙方宣佈將通過本次合作,共同探討疾病教育創新模式,探索全新合作路徑加強交流,打造創新方案,共同推動大衆疾病教育、提升公衆的疾病認知。
11月8日,大和:維持阿裏健康(00241)“跑贏大市”評級,目標價4.8港元。10月27日,中金:維持阿裏健康(00241)“跑贏行業”評級,目標價下調至4.7港元。10月26日,高盛:予阿裏健康(00241)“中性”評級,目標價5.7港元。
最新的財務數據顯示,公司於2022年1季度,營業收入205.78億人民幣,淨利潤-2.66億人民幣;營業收入同比增加32.6%,毛利潤同比增加14.02%,淨利潤同比減少177.61%。
盈立趨勢長盈模型最近一次交易信號,2022年11月2日出現關注信號,觸發價格爲3.85港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.